Ondansetron Orally Disintegrating Tablets

SOL #: SPE2D2-25-R-0018Pre-Solicitation

Overview

Buyer

DEPT OF DEFENSE

Defense Logistics Agency

DLA TROOP SUPPORT

PHILADELPHIA, PA, 19111, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/44e2d74f5e1341d4a4a0d45efbb3a79d/view

Timeline

Posted

Aug 7, 2025

Last Updated

Mar 19, 2026

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) Troop Support is soliciting proposals for Ondansetron Orally Disintegrating Tablets (ODT) to establish a national supply source for the Department of Defense (DoD), Department of Veterans Affairs (VA), Indian Health Service (IHS), and Bureau of Prisons (BoP). This unrestricted solicitation seeks to ensure product availability, consistency, and achieve volume-based pricing through a Firm-Fixed-Price requirements contract. Proposals are due by April 22, 2026, at 3:00 PM EST.

Scope of Work & Requirements

This solicitation covers the procurement of Ondansetron ODT in various strengths and counts: 4 MG (30 count), 8 MG (10 count), and 8 MG (30 count). Key requirements include:

Product Specifications: Ondansetron ODT with National Drug Code (NDC) to be specified by the bidder.
Packaging: Unit of use, child-proof closures, bottles of minimum 100cc volume with a cylindrical body and minimum 5.75" circumference. Labels must be 5.25" x 2" with 0.5" additional space for barcode and expiration date. Bidders may offer "Bottles" and/or "Blister Packaging".
Labeling: Barcode labeling at the unit-of-use package level conforming to GS1-128 or HIBCC standards.
Registrations: Product information must be registered with RXNorm, First Data Bank, and Medi-Span prior to contract performance.
Compliance: Offerors must possess FDA approval (NDA, ANDA, or Biologic License) for offered drugs by the closing date, and manufacturing facilities must have acceptable cGMP status with the FDA.
Estimated Quantities: A "Schedule of Supplies" details estimated quantities for a base year and four option years for each item, serving as a pricing and quantity reference.

Contract Details

Contract Type: Firm-fixed-price requirements contract.
Period of Performance: One base year with four option years, for a maximum term of five years.
Set-Aside: Unrestricted.
NAICS Code: 325412, with a size standard of 1300 employees.
Contract Performance Date: 45 calendar days after award.
Contract Price Effective Date: No more than 60 calendar days after award.

Submission & Evaluation

Offers must be submitted electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS). Evaluation will follow a Lowest Price Technically Acceptable (LPTA) methodology, with award made to the responsible offeror whose proposal is technically acceptable and provides the lowest evaluated aggregate price. Proposals must include a Non-Price Proposal (Volume 1) and a Price Proposal (Volume 2). Offerors are required to complete representations and certifications electronically via SAM.gov. A reverse auction may be utilized for price discussions.